MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Bibliographic Details
Main Authors:	Whicker, Margaret E., Lin, Z. Ping, Hanna, Ruth, Sartorelli, Alan C., Ratner, Elena S.
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964088/

Similar Items

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
by: Bangham, Madeleine, et al.
Published: (2016)

Olaparib in the management of ovarian cancer
by: Bixel, Kristin, et al.
Published: (2015)

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2
by: Rytelewski, Mateusz, et al.
Published: (2016)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
by: Xie, Yuan, et al.
Published: (2016)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase, Dana M, et al.
Published: (2016)

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
by: Pant, Alok, et al.
Published: (2012)

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
by: Agarwal, Ekta, et al.
Published: (2014)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
by: Simioni, Carolina, et al.
Published: (2013)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
by: Doi, Toshihiko, et al.
Published: (2015)

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells
by: Malkomes, Patrizia, et al.
Published: (2016)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
by: Ahn, Daniel H., et al.
Published: (2015)

MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation
by: Jin, Piaopiao, et al.
Published: (2016)

PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
by: Qi, Lei, et al.
Published: (2015)

Erratum to: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
by: Qi, Lei, et al.
Published: (2015)

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
by: Zhao, Yuan-Yuan, et al.
Published: (2014)

Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
by: Rehan, Mohd, et al.
Published: (2014)

Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
by: Wilson, Jacob M, et al.
Published: (2015)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
by: Shaw, Heather M, et al.
Published: (2013)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
by: Alli, Elizabeth, et al.
Published: (2011)

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
by: Hudis, Clifford, et al.
Published: (2013)

Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility
by: Che, Huan-yong, et al.
Published: (2014)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
by: Molife, L Rhoda, et al.
Published: (2014)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
by: Meng, Jieru, et al.
Published: (2013)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
by: Kim, Myung Joo, et al.
Published: (2012)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura, Katsutoshi, et al.
Published: (2012)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
by: Cheng Y, et al.
Published: (2018-09-01)

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
by: Vareki, Saman Maleki, et al.
Published: (2014)

New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
by: Plaskocinska, Inga, et al.
Published: (2016)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
by: Maistro, Simone, et al.
Published: (2016)

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
by: Schouten, Philip C., et al.
Published: (2016)

Cisplatin in breast cancer treatment in BRCA1 carriers
by: Gronwald, Jacek, et al.
Published: (2012)

Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer
by: Zhang, P, et al.
Published: (2014)

The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer
by: Wu, Wei, et al.
Published: (2014)

Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin
by: Yang, Fan, et al.
Published: (2015)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
by: Vaidyanathan, Aparajitha, et al.
Published: (2016)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
by: Ledermann, Jonathan A, et al.
Published: (2016)

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts
by: Lohse, Ines, et al.
Published: (2016)

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway
by: Ji, Dongmei, et al.
Published: (2014)

The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
by: Dongmei Ji, et al.